These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 15503027)

  • 1. Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies.
    Chen X; Bies RR; Ramanathan RK; Zuhowski EG; Trump DL; Egorin MJ
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):237-43. PubMed ID: 15503027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
    Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biliary excretion of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats.
    Musser SM; Egorin MJ; Zuhowski EG; Hamburger DR; Parise RA; Covey JM; White KD; Eiseman JL
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):139-46. PubMed ID: 12761648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice.
    Xu L; Eiseman JL; Egorin MJ; D'Argenio DZ
    J Pharmacokinet Pharmacodyn; 2003 Jun; 30(3):185-219. PubMed ID: 14571691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.
    Ramanathan RK; Trump DL; Eiseman JL; Belani CP; Agarwala SS; Zuhowski EG; Lan J; Potter DM; Ivy SP; Ramalingam S; Brufsky AM; Wong MK; Tutchko S; Egorin MJ
    Clin Cancer Res; 2005 May; 11(9):3385-91. PubMed ID: 15867239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations.
    Egorin MJ; Rosen DM; Wolff JH; Callery PS; Musser SM; Eiseman JL
    Cancer Res; 1998 Jun; 58(11):2385-96. PubMed ID: 9622079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.
    Banerji U; O'Donnell A; Scurr M; Pacey S; Stapleton S; Asad Y; Simmons L; Maloney A; Raynaud F; Campbell M; Walton M; Lakhani S; Kaye S; Workman P; Judson I
    J Clin Oncol; 2005 Jun; 23(18):4152-61. PubMed ID: 15961763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
    van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
    Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
    Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
    Lee CK; Rowinsky EK; Li J; Giles F; Moore MJ; Hidalgo M; Capparelli E; Jolivet J; Baker SD
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2158-65. PubMed ID: 16609029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of the novel anticancer agent KRN7000.
    Crul M; Mathôt RA; Giaccone G; Punt CA; Rosing H; Hillebrand MX; Ando Y; Nishi N; Tanaka H; Schellens JM; Beijnen JH
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):287-93. PubMed ID: 11914907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
    Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.
    Chung YL; Troy H; Banerji U; Jackson LE; Walton MI; Stubbs M; Griffiths JR; Judson IR; Leach MO; Workman P; Ronen SM
    J Natl Cancer Inst; 2003 Nov; 95(21):1624-33. PubMed ID: 14600095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic model of PI-88, a heparanase inhibitor.
    Hudachek SF; Eckhardt SG; Hicks B; Gustafson DL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):743-53. PubMed ID: 19633850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma.
    Johnston JS; Phelps MA; Blum KA; Blum W; Grever MR; Farley KL; Dalton JT
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Aug; 871(1):15-21. PubMed ID: 18635408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
    Latz JE; Chaudhary A; Ghosh A; Johnson RD
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):401-11. PubMed ID: 16322991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy.
    Faltaos DW; Hulot JS; Urien S; Morel V; Kaloshi G; Fernandez C; Xuan kH; Leblond V; Lechat P
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):626-33. PubMed ID: 16528531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.